Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Rifamycin - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for rifamycin and what is the scope of freedom to operate?

Rifamycin is the generic ingredient in one branded drug marketed by Cosmo Technologies and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rifamycin has twenty-six patent family members in nineteen countries.

There are eleven drug master file entries for rifamycin. One supplier is listed for this compound.

Summary for rifamycin
Recent Clinical Trials for rifamycin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, UgandaPhase 2/Phase 3
University of Turin, Turin, ItalyPhase 2/Phase 3
Joint Clinical Research Centre, Kampala, UgandaPhase 2/Phase 3

See all rifamycin clinical trials

Synonyms for rifamycin
(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate
(7S,11S,13S,17S,18S,12R,14R,15R,16R)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7 ,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<4, 7>.0<5,28>]triaconta-1(28),2,4,9,19,21,25(
(pentahydroxy-methoxy-heptamethyl-dioxo-[?]yl) acetate
14897-39-3 (unspecified hydrochloride salt)
15105-92-7
15105-92-7 (mono-hydrochloride salt)
2,7-(Epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, (2S,16S,17S,18R,19R,20R,21S,22R,23S)-
2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate
2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione,5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate
29),26-octaen-13-yl acetate
5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2-H)-dione, 21-acetate
6998-60-3
8248AH
AKOS024281286
AKOS027460740
BDBM50391000
C12044
C37H47NO12
CB-01-11
CHEBI:29673
CHEMBL437765
D02549
D0FX2Q
DTXSID1032014
DU69T8ZZPA
EINECS 230-273-3
GTPL4570
HJYYPODYNSCCOU-ODRIEIDWSA-N
LMPK05000005
LS-2172
NSC133100
Rifacin
Rifamicina
Rifamicina [INN-Spanish]
Rifamicine SV
Rifamycin (oral controlled-release, gastrointestinal-specific)
Rifamycin (oral controlled-release, gastrointestinal-specific), Cosmo/Dr Falk/Santarus
Rifamycin (USAN/INN)
Rifamycin [INN:BAN:DCF]
Rifamycin [USAN:INN:BAN:DCF]
RIFAMYCIN SODIUM
Rifamycin SV
Rifamycin SV MMX
Rifamycin SV, an antibiotic produced by certain strains of Streptomyces mediterranei, or the same substance produced by any other means
Rifamycine
Rifamycine [INN-French]
Rifamycinum
Rifamycinum [INN-Latin]
Rifocin
Rifocyn
RIFOMYCIN
Rifomycin SV
SC-49540
SCHEMBL151824
SR-01000872597
SR-01000872597-1
ST044225
Tuborin
UNII-DU69T8ZZPA
ZINC169633673

US Patents and Regulatory Information for rifamycin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Mallinckrodt
Moodys
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.